Viatris (VTRS) Research & Development (2020 - 2026)
Viatris (VTRS) posted Research & Development of $248.3 million for Q2 2026, little changed on a QoQ basis from $248.6 million in Q1 2026, and up 13.48% year-over-year from $218.8 million in Q2 2025.
Analysis
Viatris (VTRS) Research & Development (2020 - 2026) Analysis & Trends
Viatris has reported Research & Development for 7 years, with the latest figure at $248.3 million in Q2 2026.
- On a quarterly basis, Research & Development rose 13.48% year-over-year to $248.3 million in Q2 2026; TTM through Jun 2026 was $1.0 billion, a 20.85% increase from a year earlier, with the FY2025 full-year figure at $965.9 million, up 19.44% from the prior year.
- Research & Development was $248.3 million for Q2 2026 at Viatris, roughly flat from $248.6 million in the prior quarter.
- The five-year high for Research & Development was $274.7 million in Q4 2025, with the low at $142.3 million in Q1 2022.
- Average Research & Development over 5 years is $207.7 million, with a median of $205.3 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Research & Development declined 22.71% in 2022, then surged 33.03% in 2025.
- Over 5 years, Research & Development stood at $182.4 million in 2022, then gained by 11.18% to $202.8 million in 2023, then grew by 1.82% to $206.5 million in 2024, then soared by 33.03% to $274.7 million in 2025, then decreased by 9.61% to $248.3 million in 2026.
- The last three Research & Development figures came in at $248.3 million (Q2 2026), $248.6 million (Q1 2026), and $274.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.95 Bn | 2.15 Bn | 970.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 248.30 Mn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 60.90 Mn |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.33 Bn | 334.51 Mn | 39.02 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 520.75 Mn | 2.10 Bn | 173.00 Mn |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | -21.86 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 14.75 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 22.16 Mn |
| 9 | Fennec Pharmaceuticals | 411.09 Mn | 369.84 Mn | 17.15 Mn | 10.66 Mn |
| 10 | RedHill Biopharma | 181.39 Mn | 181.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 248.30 Mn |
| Mar 31, 2026 | 248.60 Mn |
| Dec 31, 2025 | 274.70 Mn |
| Sep 30, 2025 | 250.40 Mn |
| Jun 30, 2025 | 218.80 Mn |
| Mar 31, 2025 | 222.00 Mn |
| Dec 31, 2024 | 206.50 Mn |
| Sep 30, 2024 | 198.40 Mn |
| Jun 30, 2024 | 204.10 Mn |
| Mar 31, 2024 | 199.70 Mn |
| Dec 31, 2023 | 202.80 Mn |
| Sep 30, 2023 | 211.20 Mn |
| Jun 30, 2023 | 208.30 Mn |
| Mar 31, 2023 | 182.90 Mn |
| Dec 31, 2022 | 182.40 Mn |
| Sep 30, 2022 | 174.90 Mn |
| Jun 30, 2022 | 162.60 Mn |
| Mar 31, 2022 | 142.30 Mn |
| Dec 31, 2021 | 197.10 Mn |
| Sep 30, 2021 | 152.10 Mn |